Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant 177Lu-PSMA radioligand therapy before radical prostatectomy in node-positive hormone-sensitive prostate cancer
NL-OMON52075Phase 2Recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Jun 2023
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lutetium lu 177 vipivotide tetraxetan in prostate cancer (PCa), sponsored by Vrije University Medical Center. Started Jun 2023; status: recruiting.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON52075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52075.